CN102178975B - Fibrous protein hemostatic patch and making method thereof - Google Patents
Fibrous protein hemostatic patch and making method thereof Download PDFInfo
- Publication number
- CN102178975B CN102178975B CN 201110103540 CN201110103540A CN102178975B CN 102178975 B CN102178975 B CN 102178975B CN 201110103540 CN201110103540 CN 201110103540 CN 201110103540 A CN201110103540 A CN 201110103540A CN 102178975 B CN102178975 B CN 102178975B
- Authority
- CN
- China
- Prior art keywords
- fibrinogen
- thrombin
- protective agent
- paste
- stopping bleeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a fibrous protein hemostatic patch capable of being stored at room temperature. The fibrous protein hemostatic patch mainly comprises fibrinogen and thrombin derived from blood of human or mammal, and collagen derived from skin or tendon of the mammal; the fibrous protein hemostatic patch consists of the fibrinogen, the thrombin and the collagen. The fibrinogen and the thrombin are added with a protective agent, so that the fibrous protein hemostatic patch can be stored at room temperature, and has the quality guarantee period of more than 6 months and the longest quality guarantee period of 2 years. The fibrous protein hemostatic patch is suitable for locally stopping bleeding in surgeries and quickly stopping bleeding on occasions such as battlefields and disasters.
Description
Technical field
The present invention relates to biological pharmacy technical field, specifically a kind ofly can store at ambient temperature and keep fiber protein stopping bleeding paste of its function and drug effect and preparation method thereof.
Background technology
Fibrin class hemostasia products is a kind of biological product that can effectively carry out fast wound hemostasis, the advantages such as it has, and hemostasis is quick, adhesion is good, histocompatibility is good, promotion wound healing, promotion tissue regeneration.Fibrin class hemostasia products at home and abroad is widely used at present.Different according to the Fibrinogen source, fibrin class hemostasia products can be divided for people source fibrin preparation and pig source fibrin preparation two large classes; According to the difference of product forms, can be divided into again Fibrin Glue and fiber protein stopping bleeding paste two classes.
Fibrin Glue is comprised of Fibrinogen, thrombin and lysate thereof, after with lysate Fibrinogen and thrombin being dissolved respectively before using, pack in the special double syringe, with shower nozzle it is sprayed on wound surface, form rapidly the fibrin solid, play the hemostasis sealing and wait effect.Fiber protein stopping bleeding paste is the spongy dressing of lyophilizing that is formed by combining by Fibrinogen, thrombin, collagen protein.During use it directly is attached to bleeding wounds or wound surface surface, rapid reaction bonding from the teeth outwards at short notice.
The advantage that fiber protein stopping bleeding paste is compared with Fibrin Glue mainly contains: plug and play, do not need to prepare in advance, and need not dissolving, do not need loaded down with trivial details process for preparation; Ductility is better, can adapt to the movement of various organs or flexible; Also can use under the large condition of amount of bleeding; Can pressurize at fiber protein stopping bleeding paste, it is tightr that it is combined with wound.
Since the above-mentioned advantage that fiber protein stopping bleeding paste has, the sick and wounded's treatment that makes it be highly suitable for the fields such as first aid of battle field, rescue and relief work.The personnel of falling in battle on the battlefield have 50% to be because can not get giving treatment to and bleed to death timely according to statistics, and the wounded that are sent to FAMB still some owing to fail rapidly hemostasis and severe loss of blood sacrifice.Fiber protein stopping bleeding paste is easy to carry, use is simple, haemostatic effect is good, and the parent who is subject to the military medical research personnel looks at.
Fibrinogen, thrombin and collagen protein all are the protein products of biogenetic derivation, therefore have heat labile shortcoming, preserve at ambient temperature and easily cause inactivation, the degeneration of protein, thereby lose the effect of hemostasis.Usually Fibrin Glue or fiber protein stopping bleeding paste all need to be kept at the low temperature environment about 4 ℃, have limited like this scope of application, cause the inconvenience of carrying.
Protective agent in existing Fibrin Glue or the fiber protein stopping bleeding paste mainly plays protection fibrin proteinogen stable in the xeothermic techniques such as virus or irradiation of going out, and still can not reach to make it transport at ambient temperature the effect of storage.After a period of time, fibrinogenic dissolubility descends in room temperature preservation, the reduction of tiring of thrombin, and fibrinous cohesive descends until forfeiture.
Summary of the invention
The technical problem that the present invention mainly solves provides a kind of fiber protein stopping bleeding paste that can store for a long time at ambient temperature; fiber protein stopping bleeding paste has added protective agent; the effect of the existing freeze drying protectant of this protective agent; the protectant effect of inactivation of virus is arranged again, can also play the protective effect in the transportation storage.
The technical solution used in the present invention provides a kind of fiber protein stopping bleeding paste that can store for a long time; described fiber protein stopping bleeding paste comprises: Fibrinogen, thrombin, collagen protein and protective agent; described Fibrinogen and thrombin derive from people or mammalian; described collagen protein derives from mammal skin or tendon, and described protective agent is one or more of saccharide, sugar alcohol, aminoacid, salt apoplexy due to endogenous wind.
The invention has the beneficial effects as follows; fiber protein stopping bleeding paste has added protective agent; the effect of the existing freeze drying protectant of this protective agent, again the protectant effect of inactivation of virus is arranged, can also play the protective effect of transportation in storing, make the main components such as Fibrinogen, thrombin, collagen protein more stable.Thereby greatly expanded the scope of application of fiber protein stopping bleeding paste, for first aid of battle field, rescue and relief work etc. is offered help.
As a further improvement on the present invention, the concentration of following component is in the described fiber protein stopping bleeding paste: Fibrinogen 1～10mg/cm
2, thrombin 0.2～10IU/cm
2, collagen protein 0.3～10mg/cm
2
As a further improvement on the present invention, described saccharide is one or more among sucrose, the trehalose; Described sugar alcohol is one or more among mannitol, sorbitol, the xylitol; Described aminoacid is one or more among glycine, arginine, arginine hydrochloride, the histidine; Described salt is one or more among sodium chloride, sodium citrate, calcium chloride, the sodium acetate.
As a further improvement on the present invention, described fiber protein stopping bleeding paste comprises the composition of following mass percent: saccharide 2～15%, sugar alcohol 3～15%, aminoacid 5～20%, salt 3-5%.
For solving the problems of the technologies described above, another technical solution used in the present invention provides the manufacture method of above-mentioned fiber protein stopping bleeding paste, and step is as follows:
Step 1:
A, preparation Fibrinogen and thrombin:
From people or mammalian plasma, separate to obtain Fibrinogen with cold ethanol method, precipitate to remove Tween-80 and tributyl phosphate with carrying out again a cold ethanol method behind the fibrinogenolysis, obtain Fibrinogen;
Utilize the barium sulfate absorption method from people or mammalian plasma, to separate and obtain thrombinogen, obtain thrombin after activating with calcium chloride;
Preparation Fibrinogen protective agent and thrombin protective agent:
Described Fibrinogen protective agent is the dissolved in distilled water liquid of saccharide, sugar alcohol, aminoacid, four kinds of materials of salt, the dissolved in distilled water liquid that described thrombin protective agent is aminoacid and salt;
B, the Fibrinogen that obtains among the step a added dissolved in distilled water after, add the Fibrinogen protective agent for preparing in advance and mix; Behind the thrombin adding dissolved in distilled water that obtains among the step a, add the thrombin protective agent for preparing in advance and mix; Obtain fibrinogen solution and thrombin solution is for subsequent use;
Step 2, in container with behind the fibrinogen solution cryocoagulation, go up again thrombin solution and carry out freezingly, it is freezing to go up at last collagen solution, with its lyophilization, cuts packing and namely gets fiber protein stopping bleeding paste.
For solving the problems of the technologies described above, another technical solution used in the present invention provides the manufacture method of another kind of above-mentioned fiber protein stopping bleeding paste, and step is as follows:
Step 1:
A, preparation Fibrinogen and thrombin:
From people or mammalian plasma, separate to obtain Fibrinogen with cold ethanol method, precipitate to remove Tween-80 and tributyl phosphate with carrying out again a cold ethanol method behind the fibrinogenolysis, obtain Fibrinogen;
Utilize the barium sulfate absorption method from people or mammalian plasma, to separate and obtain thrombinogen, obtain thrombin after activating with calcium chloride;
Preparation Fibrinogen protective agent and thrombin protective agent:
Described Fibrinogen protective agent is the dissolved in distilled water liquid of saccharide, sugar alcohol, aminoacid, four kinds of materials of salt, the dissolved in distilled water liquid that described thrombin protective agent is aminoacid and salt;
B, the Fibrinogen that obtains among the step a added dissolved in distilled water after, add the Fibrinogen protective agent for preparing in advance and mix; Behind the thrombin adding dissolved in distilled water that obtains among the step a, add the thrombin protective agent for preparing in advance and mix; Obtain fibrinogen solution and thrombin solution is for subsequent use; Step 2: fibrinogen solution and thrombin solution are crushed into powder after the lyophilization respectively, are applied on the collagen protein of lyophilizing after mixing with the low temperature organic solvent, with the organic solvent volatilization, namely get fiber protein stopping bleeding paste.
As the further improvement of the manufacture method of above-mentioned fiber protein stopping bleeding paste, the described organic solvent of step 2 is dehydrated alcohol in the manufacture method of described fiber protein stopping bleeding paste.
The specific embodiment
By describing technology contents of the present invention in detail, realized purpose and effect, give explanation below in conjunction with embodiment is detailed.
Embodiment 1
The protective agent that the present invention selects is saccharide (sucrose, trehalose); sugar alcohol (mannitol, sorbitol, xylitol); aminoacid (glycine, arginine, arginine hydrochloride, histidine), the compositions of salt (sodium chloride, sodium citrate, calcium chloride, sodium acetate).The Fibrinogen protective agent is the dissolved in distilled water liquid of saccharide, sugar alcohol, aminoacid, four kinds of materials of salt, and the thrombin protective agent is the dissolved in distilled water liquid of aminoacid and salt, and the protective agent for preparing several groups of different components and concentration is for subsequent use.
Embodiment 2
Porcine blood plasma is carried out the deactivation of S/D method with 1% polyoxyethylene sorbitan monoleate and 0.3% tributyl phosphate, remove virus.From porcine blood plasma, separate to obtain Fibrinogen with cold ethanol method, will carry out again a cold ethanol method precipitation behind the fibrinogenolysis in order to remove polyoxyethylene sorbitan monoleate and tributyl phosphate.(Li Zhongmin, Song builds, the separation and purification that thrombin of beef is former and activity identification-Chinese Medical Sciences University's journal, 1994,5 (23): 436-437) separate from blood plasma and obtain thrombinogen, obtain thrombin after activating with calcium chloride to utilize the barium sulfate absorption method.To be dissolved into from the collagen protein that the pig tendon extracts the solution of 20mg/ml.
With Fibrinogen with dissolved in distilled water after; the Fibrinogen protective agent solution that adds in advance dissolving mixes; making final mass concentration is Fibrinogen 70mg/ml; sucrose 30mg/ml; mannitol 20mg/ml, arginine hydrochloride 35mg/ml, sodium chloride 4mg/ml; trisodium citrate 7mg/ml, vitamin B
2(the colour developing indication is used) is an amount of.
After the thrombin dissolving, the thrombin protective agent solution that adds in advance dissolving mixes, and making final mass concentration is thrombin 500IU/ml, glycine 20mg/ml, calcium chloride 4mg/ml.
With fibrinogen solution according to 0.1ml/cm
2Pour in the dull and stereotyped container, in cryogenic refrigerator, be refrigerated to fully and solidify; Then spraying thrombin solution at the Fibrinogen solid is 0.01ml/cm
2, in cryogenic refrigerator, be refrigerated to thrombin and solidify fully; On the thrombin solid, go up at last 0.5ml/cm
2Collagen solution, it is refrigerated to fully in cryogenic refrigerator solidifies.Solid after freezing is put into the freeze dryer lyophilization, after the cutting packing, carry out irradiation sterilization and go out the viral fiber protein stopping bleeding paste that stores for a long time that namely gets.
Table 1 fiber protein stopping bleeding paste room temperature preservation steadiness
The described vigor that solidifies is that blood coagulation stopped blooding the needed time after fiber protein stopping bleeding paste contacted with blood.After upper table 1 demonstration placed 25 ℃ and 37 ℃ to deposit certain hour fiber protein stopping bleeding paste, Fibrinogen still kept solidifying preferably vigor, has preferably bonding force and water absorption, can satisfy the purpose of quick-acting haemostatic powder.With do not compare at the sample of 37 ℃ of preservations, outward appearance changes not quite basically, only setting time has increased slightly, but use is not had adverse effect.
Embodiment 3:
According to embodiment 1 preparation Fibrinogen, thrombin and collagen protein.
Behind fibrinogenolysis, add the former protective agent of prior solution fibrin, making ultimate density is Fibrinogen 30mg/ml, trehalose 25mg/ml; sorbitol 20mg/ml, arginine hydrochloride 35mg/ml, glycine 10mg/ml; sodium chloride 4mg/ml, trisodium citrate 7mg/ml, vitamin B
2(the colour developing indication is used) is an amount of.
After the thrombin dissolving, add the in advance thrombin protective agent solution of dissolving, making ultimate density is thrombin 100IU/ml, glycine 20mg/ml, calcium chloride 4mg/ml.
Fibrinogen solution and thrombin solution are carried out respectively lyophilizing and carry out the dry heating method inactivation of viruses.
The solution of being dissolved into 10mg/ml from the collagen protein of pig tendon extraction, collagen solution to be poured in the dull and stereotyped container, addition is 0.5ml/cm
2, become loose collagen protein sponge after the lyophilizing, cut into certain specification.
The Fibrinogen of lyophilizing and thrombin are crushed into powder, with 4 ℃ dehydrated alcohol it are pressed 5: 1 mix homogeneously, mixed powder evenly is applied on the collagen protein sponge, under low temperature, ethanol is volatilized fully, can make fiber protein stopping bleeding paste.
Embodiment 4
According to embodiment 2 preparation Fibrinogen, thrombin and collagen protein.Design several different Fibrinogens and thrombin protective agent prescription, as shown in table 2.
Several different protective agent prescriptions of table 2 (each constituent mass percentage ratio of protective agent)
According to the method among the embodiment 3, use several different Fibrinogens and thrombin protective agent, make fiber protein stopping bleeding paste.
This fiber protein stopping bleeding paste is detected its appearance character and solidifiability 25 ℃ of insulations after 24 months, result such as following table 3:
The protection effect of three kinds of protective agent prescriptions of table 3
From upper table as seen, three kinds of protective agent prescriptions can both play and protect preferably effect.Fiber protein stopping bleeding paste 25 ℃ of insulations after 24 months outward appearance do not occur significantly to change, the vigor that solidifies is all within 10s, and is up to specification, can play preferably haemostatic effect.
The following constituent mass percentage ratio of gained fiber protein stopping bleeding paste of the present invention is: Fibrinogen 1～10mg/cm
2, thrombin 0.2～10IU/cm
2, collagen protein 0.3～10mg/cm
2, saccharide 2～15%, sugar alcohol 3～15%, aminoacid 5～20%, salt 3-5%.
The above only is embodiments of the invention; be not so limit claim of the present invention; every equivalent structure or equivalent flow process conversion that utilizes description of the present invention to do, or directly or indirectly be used in other relevant technical fields, all in like manner be included in the scope of patent protection of the present invention.
Claims (4)
1. fiber protein stopping bleeding paste, it is characterized in that, described fiber protein stopping bleeding paste comprises: Fibrinogen, thrombin, collagen protein and protective agent, described Fibrinogen and thrombin derive from people or mammalian, described collagen protein derives from mammal skin or tendon, and described protective agent is saccharide, sugar alcohol, aminoacid and salt; The concentration of following component is in the described fiber protein stopping bleeding paste: Fibrinogen 1～10mg/cm
2, thrombin 0.2～10IU/cm
2, collagen protein 0.3～10mg/cm
2Described fiber protein stopping bleeding paste comprises the composition of following mass percent: saccharide 2～15%, sugar alcohol 3～15%, aminoacid 5～20%, salt 3-5%;
Described saccharide is one or more among sucrose, the trehalose;
Described sugar alcohol is one or more among mannitol, sorbitol, the xylitol;
Described aminoacid is one or more among glycine, arginine, arginine hydrochloride, the histidine;
Described salt is one or more among sodium chloride, sodium citrate, calcium chloride, the sodium acetate.
2. the manufacture method of fiber protein stopping bleeding paste as claimed in claim 1, step is as follows:
Step 1:
A, preparation Fibrinogen and thrombin:
From people or mammalian plasma, separate to obtain Fibrinogen with cold ethanol method, precipitate to remove Tween-80 and tributyl phosphate with carrying out again a cold ethanol method behind the fibrinogenolysis, obtain Fibrinogen;
Utilize the barium sulfate absorption method from people or mammalian plasma, to separate and obtain thrombinogen, obtain thrombin after activating with calcium chloride;
Preparation Fibrinogen protective agent and thrombin protective agent:
Described Fibrinogen protective agent is the dissolved in distilled water liquid of saccharide, sugar alcohol, aminoacid, four kinds of materials of salt, the dissolved in distilled water liquid that described thrombin protective agent is aminoacid and salt;
B, the Fibrinogen that obtains among the step a added dissolved in distilled water after, add the Fibrinogen protective agent for preparing in advance and mix; Behind the thrombin adding dissolved in distilled water that obtains among the step a, add the thrombin protective agent for preparing in advance and mix; Obtain fibrinogen solution and thrombin solution is for subsequent use;
Step 2, in container with behind the fibrinogen solution cryocoagulation, go up again thrombin solution and carry out freezingly, it is freezing to go up at last collagen solution, with its lyophilization, cuts packing and namely gets fiber protein stopping bleeding paste.
3. the manufacture method of fiber protein stopping bleeding paste as claimed in claim 1, step is as follows:
Step 1:
A, preparation Fibrinogen and thrombin:
From people or mammalian plasma, separate to obtain Fibrinogen with cold ethanol method, precipitate to remove Tween-80 and tributyl phosphate with carrying out again a cold ethanol method behind the fibrinogenolysis, obtain Fibrinogen;
Utilize the barium sulfate absorption method from people or mammalian plasma, to separate and obtain thrombinogen, obtain thrombin after activating with calcium chloride;
Preparation Fibrinogen protective agent and thrombin protective agent:
Described Fibrinogen protective agent is the dissolved in distilled water liquid of saccharide, sugar alcohol, aminoacid, four kinds of materials of salt, the dissolved in distilled water liquid that described thrombin protective agent is aminoacid and salt;
B, the Fibrinogen that obtains among the step a added dissolved in distilled water after, add the Fibrinogen protective agent for preparing in advance and mix; Behind the thrombin adding dissolved in distilled water that obtains among the step a, add the thrombin protective agent for preparing in advance and mix; Obtain fibrinogen solution and thrombin solution is for subsequent use;
Step 2: fibrinogen solution and thrombin solution are crushed into powder after the lyophilization respectively, are applied on the collagen protein of lyophilizing after mixing with the low temperature organic solvent, with the organic solvent volatilization, namely get fiber protein stopping bleeding paste.
4. by the manufacture method of the described fiber protein stopping bleeding paste of claim 3, it is characterized in that described organic solvent is dehydrated alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110103540 CN102178975B (en) | 2011-04-25 | 2011-04-25 | Fibrous protein hemostatic patch and making method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110103540 CN102178975B (en) | 2011-04-25 | 2011-04-25 | Fibrous protein hemostatic patch and making method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102178975A CN102178975A (en) | 2011-09-14 |
| CN102178975B true CN102178975B (en) | 2013-10-23 |
Family
ID=44565378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110103540 Active CN102178975B (en) | 2011-04-25 | 2011-04-25 | Fibrous protein hemostatic patch and making method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102178975B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102286095B (en) * | 2011-07-06 | 2013-08-21 | 大田华灿生物科技有限公司 | Preparation method for fibrinogen |
| CN104101522A (en) * | 2013-04-10 | 2014-10-15 | 付士明 | Composite efficient blood coagulation promoting powder |
| CN104524603B (en) * | 2014-12-30 | 2018-09-25 | 广州市拜特凇医药科技有限公司 | It can be by the virus removal/ablation method for hemostasis biological products/biomaterial that living organism absorbs |
| CN104490522A (en) * | 2014-12-31 | 2015-04-08 | 武汉奥绿新生物科技有限公司 | Medical dressing for PICC (Peripherally Inserted Central Catheter) |
| CN105985940B (en) * | 2015-02-06 | 2021-07-23 | 广州倍绣生物技术有限公司 | Process for the preparation of thrombin |
| CN105056214A (en) * | 2015-06-30 | 2015-11-18 | 广西健宝石斛有限责任公司 | Dendrobium officinale haemostasis bandage |
| CN107485728A (en) * | 2016-06-12 | 2017-12-19 | 胡庆柳 | A kind of collagen fibrous proteins compound hemostatic plaster and preparation method thereof |
| CN108191968A (en) * | 2018-03-12 | 2018-06-22 | 常州市蒽盗钟情生物科技有限公司 | A kind of preparation method of human fibrinogen |
| CN112354002A (en) * | 2020-11-12 | 2021-02-12 | 广东深蓝生物科技有限公司 | Hemostatic sealant and preparation method thereof |
| CN112843326B (en) * | 2021-01-26 | 2022-11-01 | 上海利康瑞生物工程有限公司 | Fibrin adhesive quick-acting hemostatic composite powder and preparation method thereof |
| CN112972755B (en) * | 2021-03-25 | 2022-07-05 | 哈尔滨瀚邦医疗科技有限公司 | Preparation method of biological hemostatic material based on porcine fibrinogen and thrombin |
| CN113797325B (en) * | 2021-09-29 | 2023-11-21 | 复旦大学 | Method for preparing hemostatic material based on jet milling technology |
| CN116059431A (en) * | 2021-10-29 | 2023-05-05 | 丁琴琴 | Double-layer hemostatic dressing containing blood coagulation factors and preparation method thereof |
| CN114177346B (en) * | 2021-12-24 | 2023-05-26 | 中国人民解放军军事科学院军事医学研究院 | Hemostatic composition and hemostatic patch and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374830A (en) * | 1979-10-04 | 1983-02-22 | Research Corp. | Platelet aggregating material from equine arterial tissue |
| CN1386547A (en) * | 2002-06-24 | 2002-12-25 | 张清 | High-solidifiability fibrinogen gelatin |
| CN1460458A (en) * | 2003-06-13 | 2003-12-10 | 广州倍绣生物技术有限公司 | Quick biological closing hemostatic device and its production process |
| CN1552465A (en) * | 2003-06-05 | 2004-12-08 | 胡庆柳 | Fiber protein stopping bleeding paste |
-
2011
- 2011-04-25 CN CN 201110103540 patent/CN102178975B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374830A (en) * | 1979-10-04 | 1983-02-22 | Research Corp. | Platelet aggregating material from equine arterial tissue |
| CN1386547A (en) * | 2002-06-24 | 2002-12-25 | 张清 | High-solidifiability fibrinogen gelatin |
| CN1552465A (en) * | 2003-06-05 | 2004-12-08 | 胡庆柳 | Fiber protein stopping bleeding paste |
| CN1460458A (en) * | 2003-06-13 | 2003-12-10 | 广州倍绣生物技术有限公司 | Quick biological closing hemostatic device and its production process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102178975A (en) | 2011-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178975B (en) | Fibrous protein hemostatic patch and making method thereof | |
| Peng | Hemostatic agents for prehospital hemorrhage control: a narrative review | |
| Tompeck et al. | A comprehensive review of topical hemostatic agents: the good, the bad, and the novel | |
| Samudrala | Topical hemostatic agents in surgery: a surgeon's perspective | |
| Pereira et al. | Topical hemostatic agents in surgery: review and prospects. | |
| AU2012280218B2 (en) | Formulations for wound therapy | |
| Kheirabadi et al. | Clot-inducing minerals versus plasma protein dressing for topical treatment of external bleeding in the presence of coagulopathy | |
| RU2014121232A (en) | HEMOSTATIC COMPOSITIONS | |
| JP2013530955A5 (en) | ||
| CN102724968A (en) | Dry powder fibrin sealant | |
| CN103037847A (en) | Process for making dry and stable hemostatic compositions | |
| EP3752212B1 (en) | Method of making hemostatic compositions | |
| CN103816562A (en) | Rapid hemostatic product for war wounds and preparation method thereof | |
| AU2010252929B2 (en) | Dry powder fibrin sealant | |
| Hanna et al. | Fibrin sealants and topical agents in hepatobiliary and pancreatic surgery: a critical appraisal | |
| CN101351220A (en) | Thrombin-free biological adhesive and use thereof as a medicament | |
| US20200281980A1 (en) | Products and methods using a platelet-derived hemostatic agent for controlling bleeding and improving healing | |
| CN109172857A (en) | A kind of outer wound compound hemostatic material and preparation method thereof | |
| US20160121017A1 (en) | SINGLE SOLUTION of Gel-LIKE FIBRIN HEMOSTAT | |
| WO2012011429A1 (en) | Sheet preparation for tissue adhesion | |
| US20220111020A1 (en) | Hemostatic compositions and methods of making thereof | |
| WO2013021066A1 (en) | Composition in the form of a film comprising fibrinogen and a fibrinogen activator and the applications thereof | |
| US20220280606A1 (en) | Method of preparing a de-fibrinated platelet lysate, and uses of said method | |
| CN117426158B (en) | Freeze-drying production process of biological product DBT | |
| Nair et al. | Blood-derived products in wound healing and repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160811 Address after: 365000 No. 32 Industrial Park, Jing Yuan Industrial Zone, three yuan, Fujian, Sanming City Patentee after: FUJIAN HUAGENE BIOSCIENCES CO., LTD. Address before: 366100, Fujian, Sanming City province Futian road Dahua Dahua Biological Technology Co., Ltd. Patentee before: Fujian Nansheng Technology Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20220125 Address after: 361000 room 311-4, No. 2-3, Xiamei Road, Haicang District, Xiamen City, Fujian Province Patentee after: FUJIAN NANSHENG TECHNOLOGY Co.,Ltd. Address before: 365000 No. 32, Jingdong Industrial Park, Sanyuan District, Sanming City, Fujian Province Patentee before: FUJIAN HUAGENE BIOSCIENCES Co.,Ltd. |
|
| TR01 | Transfer of patent right |